AMLX logo

AMLX Amylyx Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$28.66
-1.63 (-5.38%)

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investi…

Market Cap: $3.68Bamylyx.com

Price

No data yet.

Social Signal Score

59
5d
—
30d
60
4 mentions
—
60d
58
5 mentions
—
90d
60
6 mentions
—
news: 6

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 10Hold 1Sell 0Strong Sell 0
Avg price target$49.29+72.0%
Low $39Median $52High $57
Current Consensus

Revenue

$0.00
$-1.02M$35.47M$71.96M$108.45M
Dec 2020Sep 2026

Analyst Estimates

FY2025
$-1.55
$-1.70–$-1.25
8 analysts
FY2026
$-1.51
$-1.58–$-1.45
7 analysts
FY2027
$-1.29
$-1.44–$-1.04
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Joshua Cohen
Sector
Healthcare
Industry
Biotechnology
Employees
136
Beta
-0.20
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
69.58
amylyx.com